


213.1152-CIP

**Amendments to the Specification:**

Please amend the last paragraph of page 11 of the specification as follows.


RECEIVED  
CENTRAL FAX CENTER  
DEC 08 2006



This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (currently amended) An oligonucleotide prodrug of the formula (I):



(I)

wherein:

 $R_1$  and  $R_2$  are independently H or a polymer residue; $L_1$  and  $L_4$  are independently selected releasable linking moieties; $L_2$  and  $L_3$  are independently selected bifunctional spacing groups; $X_1$  is a nucleotide or an oligonucleotide residue; $m$ ,  $n$ ,  $o$  and  $p$  are independently zero or a positive integer, provided that either  $(o + n)$  or  $(p + m) \geq 2$ ; andwherein  $L_3$  is selected from the group consisting of: